{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:57:44Z","timestamp":1790143064753,"version":"4.0.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1124\/jpet.108.142802","type":"journal-article","created":{"date-parts":[[2009,1,10]],"date-time":"2009-01-10T02:07:31Z","timestamp":1231553251000},"page":"306-313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Pharmacological Characterization of ATPM [(-)-3-Aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a Novel Mixed \u03ba-Agonist and \u03bc-Agonist\/-Antagonist That Attenuates Morphine Antinociceptive Tolerance and Heroin Self-Administration Behavior"],"prefix":"10.1016","volume":"329","author":[{"given":"Yu-Jun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Min","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Jun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Lin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Qiang","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Neumeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Gen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.108.142802_bib1","doi-asserted-by":"crossref","unstructured":"Archer S, Glick SD, and Bidlack JM (1996) Cyclazocine revisited. Neurochem Res 21: 1369-1373.","DOI":"10.1007\/BF02532378"},{"key":"10.1124\/jpet.108.142802_bib2","doi-asserted-by":"crossref","unstructured":"Bhargava HN, Gulati A, and Ramarao P (1989) Effect of chronic administration of U-50,488H on tolerance to its pharmacological actions and on multiple opioid receptors in rat brain regions and spinal cord. J Pharmacol Exp Ther 251: 21-26.","DOI":"10.1016\/S0022-3565(25)20706-6"},{"key":"10.1124\/jpet.108.142802_bib3","doi-asserted-by":"crossref","unstructured":"Bowen CA, Negus SS, Zong R, Neumeyer JL, Bidlack JM, and Mello NK (2003) Effects of mixed-action kappa\/mu opioids on cocaine self-administration and cocaine discrimination by rhesus monkeys. Neuropsychopharmacology 28: 1125-1139.","DOI":"10.1038\/sj.npp.1300105"},{"key":"10.1124\/jpet.108.142802_bib4","doi-asserted-by":"crossref","unstructured":"Butelman ER, France CP, and Woods JH (1993) Apparent pA2 analysis on the respiratory depressant effects of alfentanil, etonitazene, ethylketocyclazocine (EKC) and Mr2033 in rhesus monkeys. J Pharmacol Exp Ther 264: 145-151.","DOI":"10.1016\/S0022-3565(25)10244-9"},{"key":"10.1124\/jpet.108.142802_bib5","doi-asserted-by":"crossref","unstructured":"Crawford CA, McDougall SA, Bolanos CA, Hall S, and Berger SP (1995) The effects of the kappa agonist U-50,488 on cocaine-induced conditioned and unconditioned behaviors and Fos immunoreactivity. Psychopharmacology (Berl) 120: 392-399.","DOI":"10.1007\/BF02245810"},{"key":"10.1124\/jpet.108.142802_bib6","doi-asserted-by":"crossref","unstructured":"Davis RE, Callahan MJ, Dickerson M, and Downs DA (1992) Pharmacologic activity of CI-977, a selective kappa opioid agonist, in rhesus monkeys. J Pharmacol Exp Ther 261: 1044-1049.","DOI":"10.1016\/S0022-3565(25)11117-8"},{"key":"10.1124\/jpet.108.142802_bib7","doi-asserted-by":"crossref","unstructured":"Di Chiara G and Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 85: 5274-5278.","DOI":"10.1073\/pnas.85.14.5274"},{"key":"10.1124\/jpet.108.142802_bib8","doi-asserted-by":"crossref","unstructured":"Emmerson PJ, Liu MR, Woods JH, and Medzihradsky F (1994) Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. J Pharmacol Exp Ther 271: 1630-1637.","DOI":"10.1016\/S0022-3565(25)24051-4"},{"key":"10.1124\/jpet.108.142802_bib9","doi-asserted-by":"crossref","unstructured":"Endoh T, Matsuura H, Tajima A, Izumimoto N, Tajima C, Suzuki T, Saitoh A, Suzuki T, Narita M, Tseng L, et al. (1999) Potent antinociceptive effects of TRK-820, a novel kappa-opioid receptor agonist. Life Sci 65: 1685-1694.","DOI":"10.1016\/S0024-3205(99)00417-8"},{"key":"10.1124\/jpet.108.142802_bib10","doi-asserted-by":"crossref","unstructured":"France CP, Medzihradsky F, and Woods JH (1994) Comparison of kappa opioids in rhesus monkeys: behavioral effects and receptor binding affinities. J Pharmacol Exp Ther 268: 47-58.","DOI":"10.1016\/S0022-3565(25)38497-1"},{"key":"10.1124\/jpet.108.142802_bib11","doi-asserted-by":"crossref","unstructured":"Glick SD, Maisonneuve IM, Raucci J, and Archer S (1995) Kappa opioid inhibition of morphine and cocaine self-administration in rats. Brain Res 681: 147-152.","DOI":"10.1016\/0006-8993(95)00306-B"},{"key":"10.1124\/jpet.108.142802_bib12","doi-asserted-by":"crossref","unstructured":"He L, Fong J, von Zastrow M, and Whistler JL (2002) Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization. Cell 108: 271-282.","DOI":"10.1016\/S0092-8674(02)00613-X"},{"key":"10.1124\/jpet.108.142802_bib13","doi-asserted-by":"crossref","unstructured":"Kamei J, Zushida K, Ohsawa M, and Nagase H (2000) The antinociceptive effects of endomorphin-1 and endomorphin-2 in diabetic mice. Eur J Pharmacol 391: 91-96.","DOI":"10.1016\/S0014-2999(00)00049-2"},{"key":"10.1124\/jpet.108.142802_bib14","doi-asserted-by":"crossref","unstructured":"Kuzmin AV, Semenova S, Gerrits MA, Zvartau EE, and Van Ree JM (1997) Kappa-opioid receptor agonist U50,488H modulates cocaine and morphine self-administration in drug-naive rats and mice. Eur J Pharmacol 321: 265-271.","DOI":"10.1016\/S0014-2999(96)00961-2"},{"key":"10.1124\/jpet.108.142802_bib15","doi-asserted-by":"crossref","unstructured":"Maisonneuve IM, Archer S, and Glick SD (1994) U50,488, a kappa opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats. Neurosci Lett 181: 57-60.","DOI":"10.1016\/0304-3940(94)90559-2"},{"key":"10.1124\/jpet.108.142802_bib16","doi-asserted-by":"crossref","unstructured":"Mathews JL, Peng X, Xiong W, Zhang A, Negus SS, Neumeyer JL, and Bidlack JM (2005) Characterization of a novel bivalent morphinan possessing kappa agonist and mu agonist\/antagonist properties. J Pharmacol Exp Ther 315: 821-827.","DOI":"10.1124\/jpet.105.084343"},{"key":"10.1124\/jpet.108.142802_bib17","doi-asserted-by":"crossref","unstructured":"Mello NK, Mendelson JH, Bree MP, and Lukas SE (1990) Buprenorphine and naltrexone effects on cocaine self-administration by rhesus monkeys. J Pharmacol Exp Ther 254: 926-939.","DOI":"10.1016\/S0022-3565(25)12759-6"},{"key":"10.1124\/jpet.108.142802_bib18","doi-asserted-by":"crossref","unstructured":"Mello NK and Negus SS (1998) Effects of kappa opioid agonists on cocaine- and food-maintained responding by rhesus monkeys. J Pharmacol Exp Ther 286: 812-824.","DOI":"10.1016\/S0022-3565(24)37657-8"},{"key":"10.1124\/jpet.108.142802_bib19","doi-asserted-by":"crossref","unstructured":"Mello NK and Negus SS (2000) Interactions between kappa opioid agonists and cocaine: preclinical studies. Ann N Y Acad Sci 909: 104-132.","DOI":"10.1111\/j.1749-6632.2000.tb06678.x"},{"key":"10.1124\/jpet.108.142802_bib20","doi-asserted-by":"crossref","unstructured":"Negus SS and Mello NK (2002) Effects of mu-opioid agonists on cocaine- and food-maintained responding and cocaine discrimination in rhesus monkeys: role of mu-agonist efficacy. J Pharmacol Exp Ther 300: 1111-1121.","DOI":"10.1124\/jpet.300.3.1111"},{"key":"10.1124\/jpet.108.142802_bib21","doi-asserted-by":"crossref","unstructured":"Negus SS, Mello NK, Portoghese PS, and Lin CE (1997) Effects of kappa opioids on cocaine self-administration by rhesus monkeys. J Pharmacol Exp Ther 282: 44-55.","DOI":"10.1016\/S0022-3565(24)36769-2"},{"key":"10.1124\/jpet.108.142802_bib22","doi-asserted-by":"crossref","unstructured":"Neumeyer JL, Bidlack JM, Zong R, Bakthavachalam V, Gao P, Cohen DJ, Negus SS, and Mello NK (2000a) Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists\/antagonists as potential pharmacotherapeutics for cocaine dependence. J Med Chem 43: 114-122.","DOI":"10.1021\/jm9903343"},{"key":"10.1124\/jpet.108.142802_bib23","doi-asserted-by":"crossref","unstructured":"Neumeyer JL, Gu XH, van Vliet LA, DeNunzio NJ, Rusovici DE, Cohen DJ, Negus SS, Mello NK, and Bidlack JM (2001) Mixed kappa agonists and mu agonists\/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan. Bioorg Med Chem Lett 11: 2735-2740.","DOI":"10.1016\/S0960-894X(01)00543-1"},{"key":"10.1124\/jpet.108.142802_bib24","doi-asserted-by":"crossref","unstructured":"Neumeyer JL, Mello NK, Negus SS, and Bidlack JM (2000b) Kappa opioid agonists as targets for pharmacotherapies in cocaine abuse. Pharm Acta Helv 74: 337-344.","DOI":"10.1016\/S0165-7208(00)80039-2"},{"key":"10.1124\/jpet.108.142802_bib25","doi-asserted-by":"crossref","unstructured":"Portoghese AS, Lipkowski AW, and Takemori AE (1987) Bimorphinans as highly selective, potent kappa opioid receptor antagonists. J Med Chem 30: 238-239.","DOI":"10.1021\/jm00385a002"},{"key":"10.1124\/jpet.108.142802_bib26","doi-asserted-by":"crossref","unstructured":"Saitoh A, Yoshikawa Y, Onodera K, and Kamei J (2005) Role of delta-opioid receptor subtypes in anxiety-related behaviors in the elevated plus-maze in rats. Psychopharmacology (Berl) 182: 327-334.","DOI":"10.1007\/s00213-005-0112-6"},{"key":"10.1124\/jpet.108.142802_bib27","doi-asserted-by":"crossref","unstructured":"Schenk S, Partridge B, and Shippenberg TS (1999) U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking. Psychopharmacology (Berl) 144: 339-346.","DOI":"10.1007\/s002130051016"},{"key":"10.1124\/jpet.108.142802_bib28","doi-asserted-by":"crossref","unstructured":"Schenk S, Partridge B, and Shippenberg TS (2000) Reinstatement of extinguished drug-taking behavior in rats: effect of the kappa-opioid receptor agonist, U69593. Psychopharmacology (Berl) 151: 85-90.","DOI":"10.1007\/s002130000476"},{"key":"10.1124\/jpet.108.142802_bib29","doi-asserted-by":"crossref","unstructured":"Shippenberg TS, LeFevour A, and Heidbreder C (1996) kappa-Opioid receptor agonists prevent sensitization to the conditioned rewarding effects of cocaine. J Pharmacol Exp Ther 276: 545-554.","DOI":"10.1016\/S0022-3565(25)12305-7"},{"key":"10.1124\/jpet.108.142802_bib30","doi-asserted-by":"crossref","unstructured":"Suzuki T, Izumimoto N, Takezawa Y, Fujimura M, Togashi Y, Nagase H, Tanaka T, and Endoh T (2004) Effect of repeated administration of TRK-820, a kappa-opioid receptor agonist, on tolerance to its antinociceptive and sedative actions. Brain Res 995: 167-175.","DOI":"10.1016\/j.brainres.2003.09.057"},{"key":"10.1124\/jpet.108.142802_bib31","doi-asserted-by":"crossref","unstructured":"Suzuki T, Shiozaki Y, Masukawa Y, Misawa M, and Nagase H (1992) The role of mu- and kappa-opioid receptors in cocaine-induced conditioned place preference. Jpn J Pharmacol 58: 435-442.","DOI":"10.1016\/S0021-5198(19)39723-9"},{"key":"10.1124\/jpet.108.142802_bib32","doi-asserted-by":"crossref","unstructured":"Takemori AE, Loh HH, and Lee NM (1992) Suppression by dynorphin A-(1\u201313) of the expression of opiate withdrawal and tolerance in mice. Eur J Pharmacol 221: 223-226.","DOI":"10.1016\/0014-2999(92)90705-9"},{"key":"10.1124\/jpet.108.142802_bib33","doi-asserted-by":"crossref","unstructured":"Tallarida RJ and Murray RB (1986) Manual of Pharmacologic Calculations with Computer Programs, 2nd ed, Springer Verlag, New York.","DOI":"10.1007\/978-1-4612-4974-0"},{"key":"10.1124\/jpet.108.142802_bib34","doi-asserted-by":"crossref","unstructured":"Tao YM, Li QL, Zhang CF, Xu XJ, Chen J, Ju YW, Chi ZQ, Long YQ, and Liu JG (2008) LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential. Eur J Pharmacol 584: 306-311.","DOI":"10.1016\/j.ejphar.2008.02.028"},{"key":"10.1124\/jpet.108.142802_bib35","doi-asserted-by":"crossref","unstructured":"Tsuji M, Yamazaki M, Takeda H, Matsumiya T, Nagase H, Tseng LF, Narita M, and Suzuki T (2000) The novel kappa-opioid receptor agonist TRK-820 has no affect on the development of antinociceptive tolerance to morphine in mice. Eur J Pharmacol 394: 91-95.","DOI":"10.1016\/S0014-2999(00)00139-4"},{"key":"10.1124\/jpet.108.142802_bib36","unstructured":"Ukai M, Mizutani M, and Kameyama T (1994) Opioid peptides selective for receptor types modulate cocaine-induced behavioral responses in mice. Nihon Shinkei Seishin Yakurigaku Zasshi 14: 153-159."},{"key":"10.1124\/jpet.108.142802_bib37","doi-asserted-by":"crossref","unstructured":"Yamamoto T, Ohno M, and Ueki S (1988) A selective kappa-opioid agonist, U-50,488H, blocks the development of tolerance to morphine analgesia in rats. Eur J Pharmacol 156: 173-176.","DOI":"10.1016\/0014-2999(88)90162-8"},{"key":"10.1124\/jpet.108.142802_bib38","doi-asserted-by":"crossref","unstructured":"Zhang A, Xiong W, Hilbert JE, DeVita EK, Bidlack JM, and Neumeyer JL (2004) 2-aminothiazole-derived opioids: bioisosteric replacement of phenols. J Med Chem 47: 1886-1888.","DOI":"10.1021\/jm049978n"},{"key":"10.1124\/jpet.108.142802_bib39","doi-asserted-by":"crossref","unstructured":"Zhou W, Zhang F, Tang S, Liu H, Gu J, and Yang G (2005) The dissociation of heroin-seeking patterns induced by contextual, discriminative, or discrete conditioned cues in a model of relapse to heroin in rats. Psychopharmacology (Berl) 181: 197-206.","DOI":"10.1007\/s00213-005-2262-y"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524383648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524383648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.108.142802","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T22:05:28Z","timestamp":1744149928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524383648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S0022356524383648"],"URL":"https:\/\/doi.org\/10.1124\/jpet.108.142802","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological Characterization of ATPM [(-)-3-Aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a Novel Mixed \u03ba-Agonist and \u03bc-Agonist\/-Antagonist That Attenuates Morphine Antinociceptive Tolerance and Heroin Self-Administration Behavior","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.108.142802","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2009 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}